<DOC>
	<DOC>NCT00401583</DOC>
	<brief_summary>This is a Phase I study to determine the effect of GW786034 (pazopanib) on P450 enzymes. This study will help determine which types of drugs may interact with GW786034.</brief_summary>
	<brief_title>A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Inclusion criteria: Histologically or cytologically confirmed diagnosis of advanced solid tumors. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate bone marrow, renal, lung, and liver function. A female subject must not be pregnant and will agree not to become pregnant during the trial Exclusion criteria: Any major surgery, chemotherapy, hormone therapy, investigational drugs, or radiotherapy within the last 28 days. Poorly controlled hypertension. Corrected QT (QTc) prolongation defined as a QTc interval greater than or equal to 480 msec and a prior history of cardiovascular disease, arrhythmias, or significant ECG abnormalities. Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the last 3 months. Current use of therapeutic anticoagulation (low molecular weight heparin, oral anticoagulant agents). Amiodarone must not have been taken for at least 6 months prior to the administration of the first dose of study drug. History of brain metastases. Has narrowangle glaucoma which is a contraindication to midazolam use. History of nicotinecontaining product (including cigarettes, cigars, nicotine patches) use within the past 6 months. A history of bleeding problems.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>GW786034 (pazopanib) cytochrome P450 interaction</keyword>
</DOC>